Redose
Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist that the FDA has approved under three brand names: Ozempic and Wegovy as once-weekly subcutaneous injections, and Rybelsus as a daily oral tablet. It is one of the most studied compounds in its class, with a substantial clinical trial record covering type 2 diabetes management, cardiovascular risk reduction, and chronic weight management in adults with obesity.
What Is Semaglutide
Semaglutide is a 31-amino-acid peptide analog of human GLP-1, a naturally occurring gut hormone released after eating. Novo Nordisk developed it with structural modifications to extend its half-life from the roughly two-minute half-life of native GLP-1 to approximately one week. Those modifications include an albumin-binding fatty diacid chain and targeted amino acid substitutions that resist breakdown by the enzyme DPP-4.
The result is a compound stable enough to be dosed once weekly by injection or, in a formulated oral version, once daily by tablet. It is not considered a research-only or investigational peptide: all three brand formulations carry full FDA approval with defined indications, prescribing guidance, and post-market safety monitoring.
How It Works
Semaglutide binds to GLP-1 receptors found in the pancreas, brain, gut, and other tissues. In the pancreas, receptor activation stimulates insulin secretion in a glucose-dependent manner, meaning insulin release increases when blood glucose is elevated and decreases at normal glucose levels. This mechanism significantly reduces the hypoglycemia risk associated with older diabetes medications.
At the same time, semaglutide suppresses glucagon secretion, slows gastric emptying, and acts on appetite-regulating centers in the hypothalamus and brainstem to reduce hunger and increase satiety signals. The combined effect of reduced caloric intake and improved insulin sensitivity accounts for both the glycemic and weight-loss outcomes observed in clinical trials.
Because the insulinotropic effect is glucose-dependent, GLP-1 agonists like semaglutide carry a lower intrinsic hypoglycemia risk compared to insulin or sulfonylureas, though hypoglycemia risk increases when combined with those agents.
What the Research Says
The SUSTAIN trial program established semaglutide's efficacy and safety for type 2 diabetes, demonstrating meaningful HbA1c reductions across multiple trials. The SUSTAIN-6 trial also showed a statistically significant reduction in major adverse cardiovascular events (MACE) in adults with type 2 diabetes and high cardiovascular risk.
For weight management, the STEP trial program evaluated once-weekly semaglutide 2.4 mg. In STEP 1 and STEP 3, participants without type 2 diabetes achieved placebo-subtracted mean body weight reductions of approximately 10 to 12 percent over 68 weeks. The two-year STEP 5 trial demonstrated that weight loss was largely maintained with continued treatment, and that much of the lost weight returned after discontinuation. These are clinically significant findings, though they represent group averages and individual variation is substantial.
The SELECT trial, published in 2023, extended the cardiovascular indication: semaglutide 2.4 mg reduced the risk of serious cardiovascular events in adults with overweight or obesity and established cardiovascular disease but without type 2 diabetes, leading to an updated FDA approval for that use.
Research into additional applications, including non-alcoholic steatohepatitis (MASH), addiction-related behaviors, and other metabolic conditions, is ongoing. Results from those areas should be treated as preliminary until confirmed by larger trials.
Typical Dosing
The following reflects dosing schedules described in FDA-approved prescribing information and published clinical trial protocols. This is not personal dosing instruction. All semaglutide use should be supervised by a qualified healthcare provider.
| Formulation | Starting Dose | Titration Steps | Target Maintenance |
|---|---|---|---|
| Ozempic (injectable, diabetes) | 0.25 mg/week x 4 weeks | 0.5 mg, then 1 mg, then 2 mg if needed | 0.5 to 2 mg/week |
| Wegovy (injectable, weight) | 0.25 mg/week x 4 weeks | 0.5, 1.0, 1.7 mg at 4-week intervals | 2.4 mg/week |
| Rybelsus (oral, diabetes) | 3 mg/day x 30 days | 7 mg/day, then 14 mg/day if needed | 7 to 14 mg/day |
Dose escalation is gradual by design. Jumping to a higher dose too quickly substantially increases the frequency and severity of gastrointestinal side effects without proportional additional benefit. Steady-state plasma concentrations develop over approximately four to five weeks of weekly injections.
For guidance on injection technique or rotating sites to reduce local reactions, see the injection site rotation guide.
Side Effects and Safety
Gastrointestinal effects are the most common adverse events across all formulations and indications. Nausea occurs in a meaningful proportion of users, particularly during dose escalation, and is the primary reason for discontinuation in trials. Diarrhea, vomiting, constipation, and abdominal discomfort are also frequently reported. These effects typically diminish as the body adjusts, but they can be persistent in some individuals.
More serious considerations include:
- Pancreatitis: Acute pancreatitis has been reported. Semaglutide should be discontinued if pancreatitis is suspected and not restarted if confirmed.
- Gallbladder disease: Cholelithiasis (gallstones) and cholecystitis have been observed at higher rates in treated patients, consistent with findings for other GLP-1 agonists.
- Thyroid C-cell tumors: Semaglutide carries an FDA boxed warning based on findings in rodent studies. The direct relevance to humans is not established, but the drug is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2).
- Hypoglycemia: Low risk when semaglutide is used alone; higher risk when combined with insulin or sulfonylureas.
- Delayed gastric emptying: Can affect absorption of oral medications, particularly those with narrow therapeutic windows. This interaction is clinically relevant for patients on oral contraceptives or other time-sensitive oral drugs.
- Kidney function: Severe dehydration from GI side effects can impair kidney function. Adequate hydration during dose escalation is important.
Contraindications include a personal or family history of medullary thyroid carcinoma, MEN2, and prior serious hypersensitivity reactions to semaglutide. Safety in pregnancy and lactation has not been established.
Tracking Semaglutide with Redose
Once-weekly dosing sounds simple, but staying consistent week over week, monitoring for dose escalation milestones, and tracking how your body is responding are where most people slip up. Redose is built for exactly this. Log each injection in seconds, set a recurring weekly reminder, and watch your protocol history build automatically.
The free reconstitution and dose calculator covers semaglutide vial math if you are using compounded preparations under medical supervision, helping you convert concentrations, calculate draw volumes, and avoid arithmetic errors. Download Redose to keep your semaglutide protocol organized from the first dose.
This profile is educational information, not medical advice. Talk to a qualified healthcare provider before starting any protocol.